Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 18/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20072611 | 0.90 | PHGDH (1.00) | PHGDHSMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL20072492 | 0.87 | PHGDH (1.00) | PHGDHSMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL20063179 | 0.86 | PHGDH (0.82) | PHGDHKMT2ARAB9ACACNA1BAPBA1 | |
| SCHEMBL28408134 | 0.85 | PHGDH (0.74) | PHGDH | |
| SCHEMBL20063166 | 0.82 | PHGDH (0.84) | PHGDH | |
| SCHEMBL28397431 | 0.81 | PHGDH (0.67) | PHGDHSMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL20063172 | 0.80 | PHGDH (0.78) | PHGDHKMT2ARAB9ACACNA1BAPBA1 | |
| SCHEMBL20063098 | 0.80 | PHGDH (0.83) | PHGDHKMT2ARAB9ACACNA1BAPBA1 | |
| SCHEMBL20072483 | 0.79 | PHGDH (1.00) | PHGDH | |
| SCHEMBL20072331 | 0.78 | PHGDH (0.82) | PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225469-B2 | Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-01-18 | — | — | US | disclosed |
| US-20180105508-A1 | INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225469-B2 | Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof | PHGDH, PGD, PGK1 | PHGDH 1/4885SMN1; SMN2 4644/4885KMT2A 3959/4885 |
| US-20180105508-A1 | INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF | PHGDH, PGD, PGK1 | PHGDH 1/4885SMN1; SMN2 4643/4885KMT2A 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.